Methadone: The Enduring Pillar of Opioid Recovery

Methadone is a synthetic opioid that has been the cornerstone of addiction treatment for over half a century. Synthesized in Germany in 1937 as an alternative to Morphine during wartime shortages, it was later discovered to be an exceptionally effective tool for managing opioid withdrawal and cravings. In India, Methadone is primarily used in Methadone Maintenance Treatment (MMT) programs, specifically designed for individuals with long-term Heroin or pharmaceutical opioid dependence who have not succeeded with Buprenorphine-based therapy.

This seventh installment of our series provides an exhaustive analysis of Methadone in India for 2026.

---

1. Substance Profile & Classification

• Generic Name: Methadone Hydrochloride
• Chemical Class: Diphenylpropylamine (Synthetic Opioid)
• Therapeutic Class: Full opioid agonist / NMDA receptor antagonist
• Indian Legal Status:
  • Essential Narcotic Drug (END): Like Morphine, Methadone is classified as an END under the 2014 NDPS Amendment. This allows specialized hospitals and “Recognized Medical Institutions” (RMIs) to stock and dispense it under strict supervision.
  • NDPS Act Status: Strictly regulated. Possession without an “Essential Narcotic Drug” prescription from an authorized practitioner is a non-bailable offense.
  • Commercial Quantity: 50 grams (dry weight).

---

2. Market Availability and Pricing in India (May 2026)

Methadone is available in India almost exclusively as an Oral Syrup (5mg/ml or 10mg/ml). It is an institutional drug and is not available in retail commerce.

A. PMBJP (Jan Aushadhi Kendra) Availability

❌ Methadone is NOT available in Jan Aushadhi Kendras. Its status as an Essential Narcotic Drug (END) requires highly specialized storage and daily observed treatment (DOT) protocols which are incompatible with the PMBJP retail model.

B. Institutional Procurement and DOT Pricing

Methadone is supplied directly to Recognized Medical Institutions (RMIs) and government-run Drug Treatment Clinics (DTCs).

Formulation	Primary Manufacturer	Clinic Type	Approx. Patient Cost (INR)
Methadone Syrup (5mg/ml)	Rusan Pharma	Government OST/DTC	FREE (NACO/State Govt)
Methadone Syrup (10mg/ml)	Rusan Pharma	Private ATF/RMI	₹180.00 – ₹280.00 (Bottle)

[!IMPORTANT] Daily Observed Treatment (DOT): In 2026, patients do not “take home” Methadone. You must consume your dose in the presence of a medical professional at the clinic to prevent diversion and ensure safety.

[!IMPORTANT] In most cases, patients do not “buy” Methadone; they pay for a “treatment package” at a de-addiction center which includes the medication, counseling, and medical monitoring.

---

3. Clinical Pharmacology: The NMDA Advantage

Mechanism of Action

Methadone is a Full Mu-Opioid Receptor Agonist, but it has a second, unique property:

1. Mu-Agonism: It fully activates the mu-receptors, providing a steady “baseline” of opioid effect that stops withdrawal without causing the “peaks and valleys” of shorter-acting drugs like Heroin.
2. NMDA Receptor Antagonism: Methadone is an antagonist at the N-methyl-D-aspartate (NMDA) receptor. This property is thought to prevent the development of opioid tolerance and is highly effective in treating neuropathic pain (pain from nerve damage).

Pharmacokinetics: The “Storage” Drug

• Bioavailability: High (80-90% absorbed orally).
• The Half-Life Challenge: Methadone has an exceptionally long and unpredictable half-life, ranging from 8 to 59 hours (average 24 hours).
• Accumulation: Because it lasts so long, the drug can build up in the body over several days. A dose that feels “fine” on Monday might become “toxic” by Thursday if the accumulation is not monitored.
• Excretion: Primarily via the liver and feces, making it relatively safer for patients with kidney disease than Morphine.

---

4. Euphoria and the “MMT Effect”

Euphoria Profile

• Oral Route: When taken as a syrup, Methadone has a slow onset (30–60 minutes). It does not provide the “rush” associated with injected drugs. Instead, it provides a long-lasting, heavy sedation.
• “The Wall”: High-dose Methadone maintenance creates a “blockade” effect. If a patient on a stable dose of Methadone tries to use Heroin, they will often feel nothing, because the Methadone is already occupying the receptors.

---

5. Critical Risks: Toxicity and QT Prolongation

A. Lethal Dose

Methadone is one of the most common causes of accidental pharmaceutical overdose worldwide.

• Opioid-Naive Individuals: A single dose of 20mg to 30mg can be fatal for a non-user.
• Pediatric Danger: For a child, as little as 5mg (1ml of standard syrup) can cause fatal respiratory arrest.

B. Heart Health (QT Prolongation)

Methadone can affect the electrical activity of the heart, specifically prolonging the QT interval. This can lead to a potentially fatal heart rhythm called Torsades de Pointes.

• Clinical Rule: Patients on high-dose Methadone (>100mg) should have regular ECGs to monitor their heart rhythm.

---

6. Methadone vs. Buprenorphine: The Indian Context

In India, the choice between Buprenorphine (Part 6) and Methadone is clinical:

• Buprenorphine: Preferred for younger patients, those with shorter addiction histories, or those who need “take-home” doses. It is safer (due to the ceiling effect).
• Methadone: Preferred for “heavy” users with massive Heroin tolerance, those who fail on Buprenorphine, or those with chronic pain. It is more effective at stopping severe cravings but requires more strict daily supervision.

---

7. Legal Status and Diversion

As an Essential Narcotic Drug, Methadone diversion is a top priority for the Narcotics Control Bureau (NCB).

• The “Take-Home” Problem: Unlike Buprenorphine, which is often given as a multi-day supply in some programs, Methadone is almost always “Liquid-Under-Lid”—meaning the patient must drink it in front of the nurse. This is to prevent the syrup from being sold on the black market.
• Penalties: Under the NDPS Act, the illegal sale or diversion of Methadone by a medical practitioner carries a mandatory minimum sentence of 10 years of rigorous imprisonment.

---

8. Addiction and Recovery: The MMT Journey

Methadone Maintenance Treatment (MMT) is often a long-term commitment.

1. Induction: Starting at a low dose (10-20mg) and slowly increasing to avoid accumulation toxicity.
2. Stabilization: Finding the “Goldilocks” dose that stops cravings but doesn’t cause over-sedation.
3. Withdrawal: Methadone withdrawal is notoriously long. While Heroin withdrawal lasts 5-7 days, Methadone withdrawal can last 3 to 6 weeks. This is why “Cold Turkey” from Methadone is never recommended.

Resources for Help in India

• AIIMS NDDTC (National Drug Dependence Treatment Centre): The pioneer of Methadone treatment in India.
• Punjab State OST Program: Has the highest number of MMT patients in India.
• Helpline: 14446 (National Drug De-addiction Helpline).

---

9. Harm Reduction Strategies

• Never “Double-Dose”: If you miss a dose, do NOT take two the next day. The long half-life means you still have the drug in your system.
• Alcohol & Benzodiazepines: These are the primary killers of patients on Methadone. Combining Methadone with Alprazolam (Alprax) or Alcohol increases the risk of fatal respiratory arrest by 500%.
• Safe Storage: Methadone syrup often looks like “juice” or “water.” It MUST be stored in child-proof containers and locked away.

---

Next in the Series: Part 8: Alprazolam – The Panic Pill and the Xanax Era

Disclaimer: This series is for educational and harm-reduction purposes only. Methadone is a powerful clinical tool that must only be used under the supervision of a specialized MMT center or psychiatrist.